Ovid Therapeutics Inc. (OVID)

NASDAQ: OVID · IEX Real-Time Price · USD
3.160
+0.110 (3.61%)
Mar 28, 2024, 12:34 PM EDT - Market open
3.61%
Market Cap 215.67M
Revenue (ttm) 391,695
Net Income (ttm) -52.34M
Shares Out 70.71M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE 1.79
Dividend n/a
Ex-Dividend Date n/a
Volume 37,994
Open 3.060
Previous Close 3.050
Day's Range 3.040 - 3.170
52-Week Range 2.400 - 4.139
Beta 0.72
Analysts Strong Buy
Price Target 8.00 (+153.17%)
Earnings Date Mar 8, 2024

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex an... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 5, 2017
Employees 40
Stock Exchange NASDAQ
Ticker Symbol OVID
Full Company Profile

Financial Performance

In 2023, OVID's revenue was $391,695, a decrease of -73.93% compared to the previous year's $1.50 million. Losses were -$52.34 million, -3.38% less than in 2022.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 153.17% from the latest price.

Price Target
$8.0
(153.17% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and ...

20 days ago - GlobeNewsWire

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

4 weeks ago - GlobeNewsWire

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

7 weeks ago - GlobeNewsWire

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

NEW YORK, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

4 months ago - GlobeNewsWire

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies...

5 months ago - GlobeNewsWire

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026

NEW YORK and SAN DIEGO, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines that transform the lives of people with r...

5 months ago - GlobeNewsWire

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and ...

6 months ago - GlobeNewsWire

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...

6 months ago - GlobeNewsWire

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...

6 months ago - GlobeNewsWire

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and ...

7 months ago - GlobeNewsWire

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies...

8 months ago - GlobeNewsWire

Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and ...

8 months ago - GlobeNewsWire

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies...

9 months ago - GlobeNewsWire

Ovid Therapeutics Added to Russell 3000® Index

NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

9 months ago - GlobeNewsWire

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

NEW YORK, May 05, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies ...

11 months ago - GlobeNewsWire

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) --  Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

11 months ago - GlobeNewsWire

Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID) reports that Takeda Pharmaceuticals presented interim data at the 2023 annual meeting of the American Academy of Neur...

11 months ago - GlobeNewsWire

Texas abortion pill decision ‘threatens the health of America,' Ovid Therapeutics CEO says

Ovid Therapeutics CEO Jeremy Levin joins Yahoo Finance Live's Anjalee Khemlani to discuss a Texas judge's ruling on an abortion pill ban, drugmakers opposing the decision, uncertainty for pharmaceutic...

1 year ago - Yahoo Finance

Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a  biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies an...

1 year ago - GlobeNewsWire

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and...

1 year ago - GlobeNewsWire

Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum

NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...

1 year ago - GlobeNewsWire

Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures

NEW YORK, March 08, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives o...

1 year ago - GlobeNewsWire

Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

1 year ago - GlobeNewsWire

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

NEW YORK, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of...

1 year ago - GlobeNewsWire

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment Options A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Li...

1 year ago - GlobeNewsWire